HOME >> MEDICINE >> NEWS
Animal studies indicate new approach for treating end-stage skin and kidney cancers

New Orleans, La., March 26, 2001 Advanced skin and end-stage kidney cancer patients may have a better chance of survival with drugs developed from a new synthetic enzyme that significantly improves the effectiveness of existing interleukin-2 (IL-2) cancer therapy, based on research presented today at the American Association for Cancer Research 92nd Annual Meeting.

In animal studies conducted by researchers at the Huntsman Cancer Institute in Salt Lake City, UT, and MetaPhore Pharmaceuticals in St. Louis, MO, the synthetic enzyme M40403 showed an ability to reverse the extreme blood-pressure drop that is a common side effect of high-dosage IL-2 cancer therapy. The research also showed that the compound enhances the anti-cancer properties of IL-2 therapy.

IL-2 immunotherapy, which works by activating natural killer (NK) cells that have the ability to recognize and destroy many types of tumors, is an approved treatment for inoperable metastatic melanoma and metastatic renal cell carcinoma. About 80,000 cases of melanoma and renal cell carcinoma are diagnosed in the U.S. each year.

IL-2 use is limited, however, by potentially life threatening side effects, including hypotension, particularly at the high-dosage level indicated for these end-stage cancers. A majority of patients undergoing high-dosage IL-2 treatment currently either require intensive care unit (ICU) intervention and/or are unable to complete the full course of treatment.

Reseachers administered the synthetic enzyme, which mimics the action of a natural enzyme, superoxide dismutase (SOD), as a co-therapy with IL-2 in several animal models of advanced cancer. Previous studies have confirmed that the synthetic enzyme effectively reproduces the free-radical fighting properties of the natural SOD enzyme, which has been found to be deficient in cancer states.

When in excess, free radicals particularly superoxide anions have been shown to deactivate a class of molecules, calle
'"/>

Contact: Punnie Donohue
pdonohue@kupperparker.com
314-290-2014
Kupper Parker Communications
25-Mar-2001


Page: 1 2 3 4

Related medicine news :

1. Animal study shows link between nicotine and atrial flutter
2. Animal studies show stem cells might make biological pacemaker
3. Animal study suggests safer immunization approach to Alzheimers
4. Animal model, new grant, propel UB researchers forward in search for tinnitus treatment
5. Animal model shows early promise for SARS vaccine
6. Understanding Alzheimers disease: Animal research points to new direction for therapy
7. Animal studies prove hormone replacement therapy improves memory, report Pitt researchers
8. Animal-based nutrients linked with higher risk of stomach and esophageal cancers
9. Animal study show that heat-sensitive liposome improves chemotherapy delivery to tumors
10. Animal model shows pain and tissue injury in newborns alters nerve circuitry and reaction to pain later in life
11. AVANT Atherosclerosis Vaccine Raises HDL, Reduces Atherosclerosis In Vaccinated Animals

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2017)... ... March 27, 2017 , ... Biotechnology and ... and engagement over the household brands of Top-20 pharma by optimizing clinical trial ... partnering with the right outsourcing payments provider can provide the technology, infrastructure, and ...
(Date:3/27/2017)... , ... March 27, 2017 , ... ... organization behind the New England Journal of Medicine and NEJM Journal Watch, announces ... Pediatrics Board Review was created by a panel of pediatricians from leading medical ...
(Date:3/27/2017)... Orion, Michigan (PRWEB) , ... March 27, 2017 ... ... results. The comprehensive weight management program at Women’s Excellence will help patients ... initial evaluation and physical exam. The specialists at Women's Excellence will measure ...
(Date:3/27/2017)... ... ... Janet Schloz is still in shock after receiving a $2,500 Academic Award from California ... she said. , She thinks the coming week is going to be a very joyful ... to help my students.” , The award will allow the 4th grade teacher at Tumwater ...
(Date:3/27/2017)... ... March 27, 2017 , ... ?Grow Healthy Vending ... the pending litigation between itself and 1800 Vending DBA Healthy You Vending. (Civil ... am thrilled to announce that we have now reached a settlement agreement regarding ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... SAN FRANCISCO , March 27, 2017  Twist ... high-quality DNA synthesis, today announced that it raised an ... a total of $166 million. "It ... as we expand our reach and continue to deliver ... in multiple market segments," commented Emily M. Leproust, Ph.D., ...
(Date:3/27/2017)...   Genprex, Inc. , a privately held, clinical-stage biopharmaceutical company ... the Company,s Chief Operating Officer, is scheduled to present a corporate ... 5th Annual Cancer BioPartnering & Investment Forum: Tuesday, March 28, 2017 ... ... 24th Annual Future Leaders in Biotech Industry – Friday, April 7, ...
(Date:3/24/2017)... PORTLAND, Oregon and PUNE, India , March 24, 2017 ... in 2015, and is estimated to reach $2,614 million by 2022, Globally, registering a ... expected to generate the highest revenue, and is projected to dominate the market during ... ... Allied Market Research Logo ...
Breaking Medicine Technology:
Cached News: